Back to Search
Start Over
Current Understanding of Urachal Adenocarcinoma and Management Strategy
- Source :
- Current oncology reports. 22(1)
- Publication Year :
- 2020
-
Abstract
- The aim of this review is to sum up the state of the art of urachal carcinoma (UC) in order to easily guide clinicians. UC is a rare and aggressive disease with consequent few data about diagnosis and treatment. Dates are mainly based on retrospective trial and case reports with limited prospective trial. Clinical presentation is not specific, often with urinary symptoms. Diagnosis is mainly based on CT scan and MRI, useful to evaluate local invasion and nodal status and to detect the presence of distant metastases. Therefore, biopsy is needed to obtain histological confirmation. Surgery is the gold standard for localized disease, while different chemotherapy schemes have been used in metastatic setting. Novel findings based on mutational analysis of the tumor include the use of biological treatment, such as cetuximab, and immunotherapy, such as atezolizumab, with satisfactory responses, suggesting that personalized treatment could be the most suitable option for UC.
- Subjects :
- 0301 basic medicine
medicine.medical_specialty
medicine.medical_treatment
Adenocarcinoma
Cystectomy
03 medical and health sciences
0302 clinical medicine
Antineoplastic Agents, Immunological
Atezolizumab
Biopsy
Biomarkers, Tumor
Medicine
Humans
Molecular Targeted Therapy
Chemotherapy
medicine.diagnostic_test
Cetuximab
business.industry
Urachal carcinoma
Immunotherapy
Gold standard (test)
Prognosis
030104 developmental biology
Oncology
Urinary Bladder Neoplasms
Chemotherapy, Adjuvant
030220 oncology & carcinogenesis
Localized disease
Radiology
business
medicine.drug
Subjects
Details
- ISSN :
- 15346269
- Volume :
- 22
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- Current oncology reports
- Accession number :
- edsair.doi.dedup.....82a652e1403ac0b66af10bb53396bc3d